The pharmacoeconomics of dementia therapies: Bringing the clinical, research and economic perspectives together

Drugs and Aging

Volumn 10, Issue 3, 1997, Pages 219-233

  Molnar, Frank J ^a   Dalziel, William B ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DONEPEZIL; RIVASTIGMINE; TACRINE;

AGED; ALZHEIMER DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; FINANCE; GOVERNMENT; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE SYSTEM; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; MULTIINFARCT DEMENTIA; PHARMACOECONOMICS; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0030949738     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710030-00006     Document Type: Review

References (44)

1. Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics 1992; 1(1): 20-32
2. Sacristán JA, Soto J, Galende I. Evaluation of pharmacoeconomic studies: utilization of a checklist. Ann Pharmacother 1993; 27: 1126-33
3. Souetre EJ, Qing W, Hardens M. Methodologic approaches to pharmacoeconomics. Fundam Clin Pharmacol 1994; 8: 101-7
4. Knopman D. Tacrine for Alzheimer's disease: costs and benefits. Pharmacoeconomics 1995; 7 (4): 275-9
5. Max W. The cost of Alzheimer's disease: will drug treatment ease the burden? Pharmacoeconomics 1996; 9 (1): 5-10
6. Amar K, Wilcock G. Vascular dementia. BMJ 1996; 312: 227-31
7. Butler RN, Ahronheim J, Fillet H. Vascular dementia: an updated approach to patient management. Geriatrics 1994; 49 (1): 39-46
8. Hachinsky V. Preventable senility: a call for action against the vascular dementias. Lancet 1992; 340: 645-8
9. Hachinsky V Vascular dementia: a radical redefinition. Dementia 1994; 5: 130-2
10. Meyer JS, Judd BW, Tawaklna T, et al. Improved cognition after control of risk factors for multi-infarct dementia. JAMA 1986; 256 (16): 2203-9
11. Meyer JS, Rogers RL, McClintick K, et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia: a pilot study. J Am Geriatr Soc 1989; 37: 549-55
12. Meyer JS, Obara K, Maramatsu K, et al. Cognitive performance afler small strokes correlates with ischemia, not atrophy of the brain. Dementia 1995; 6: 312-22
13. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465-79
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
15. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS - ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44
16. Rockwood K, Parhad I, Hachinsky V. Diagnosis of vascular dementia: consortium of Canadian Centers for Clinical Cognitive Research consensus statement. Can J Neurol Sci 1994; 21: 358-64
17. Brust JCM. Vascular dementia reconsidered. Cerebrovasc Dis 1993; 3: 26-9
18. Ritchie K, Kildea D, Robine JM. The relationship between age and the prevalence of senile dementia: a meta-analysis of recent data. Int J Epidemiol 1992; 21 (4): 763-9
19. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980 - 1990 findings. Int J Epidemiol 1991; 20 (3): 736-48
20. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994; 150 (6): 899-912
21. Kramer M, German PS, Anthony JC, et al. Patterns of mental disorder among the elderly residents of eastern Baltimore. J Am Geriatr Soc 1985; 33: 236-45
22. Weissman MM, Myers JK, Tischler GL, et al. Psychiatric disorders (DSM III) and cognitive impairment in the elderly in a US urban community. Acta Psychiatr Scand 1985; 71: 366-79
23. Hasegawa K, Homma A, Imai Y. An epidemiological study of age-related dementia in the community. Int J Geriatr Psychiatry 1986; 1: 45-55
24. Rocca WA, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. Ann Neurol 1991; 30 (3): 381-90
25. Population aging and the elderly: current demographic analysis. Ottawa: Statistics Canada, 1993
26. Rockwood K, Stadnyk K. The prevalence of dementia in the elderly: a review. Can J Psychiatry 1994; 39: 253-7
27. Coughlin TA, Liu K. Health care costs of older persons with cognitive impairments. Gerontologist 1989; 29 (2): 173-82
28. Hu T, Huang L, Cartwright WS. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 1986; 26 (2): 158-63
29. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff 1993; 12: 164-76
30. Stommel M, Collins CE, Given BA. The costs of family contributions to the care of persons with dementia. Gerontologist 1994; 34 (2): 199-205
31. Welch HG, Walsh JS, Larson EB. The cost of institutional care in Alzheimer's disease: nursing home and hospital use in a prospective cohort. J Am Geriatr Soc 1992; 40: 221-4
32. Hay JW, Ernst RL. The economic costs of Alzheimer's disease. Am J Public Health 1987; 77 (9): 1169-75
33. Ernst R, Hay J. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 8: 1261-4
34. Max W. The economic impact of Alzheimer's disease. Neurology 1993; 43 Suppl. 4: S6-10
35. Huang L, Cartwright WS, Hu R. The economic cost of senile dementia in the United States, 1985. Public Health Rep 1988; 103: 3-7
36. Østbye T, Crosse E. Net economic costs of dementia in Canada. Can Med Assoc J 1994; 151 (10): 1457-64
37. Dalziel WB. Dementia: no longer the silent epidemic. Can Med Assoc J 1994; 151 (10): 1407-9
38. Mundell I. Is tacrine worth the price? Inpharma 1993; 910: 3-4
39. Lubeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer's disease. Med Interface 1994; 7 (10): 130-8
40. Rockwood K. Integration of research methods and outcome measures: comprehensive care for the frail elderly. Can J Aging 1995; 14 Suppl. 1: 151-64
41. Rockwood K. Use of global assessment measures in dementia drug trials. J Clin Epidemiol 1994; 47 (1): 101-3
42. Howard K, Rockwood K. Quality of life in Alzheimer'sdisease. Dementia 1995; 6: 113-6
43. Canadian study of health and aging: patterns of caring for persons with dementia in Canada. Can J Aging 1994; 13 (4): 470-87
44. Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics 1996; 9 (6): 535-59